As of 2026-06-15, the Intrinsic Value of Basilea Pharmaceutica AG (BSLN.SW) is 71.35 CHF. This BSLN.SW valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 49.80 CHF, the upside of Basilea Pharmaceutica AG is 43.30%.
The range of the Intrinsic Value is 55.99 - 101.70 CHF
Based on its market price of 49.80 CHF and our intrinsic valuation, Basilea Pharmaceutica AG (BSLN.SW) is undervalued by 43.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 55.99 - 101.70 | 71.35 | 43.3% |
| DCF (Growth 10y) | 65.03 - 118.25 | 82.97 | 66.6% |
| DCF (EBITDA 5y) | 40.97 - 50.63 | 45.52 | -8.6% |
| DCF (EBITDA 10y) | 52.16 - 67.64 | 59.19 | 18.9% |
| Fair Value | 74.96 - 74.96 | 74.96 | 50.53% |
| P/E | 40.96 - 46.50 | 44.03 | -11.6% |
| EV/EBITDA | 29.36 - 48.19 | 38.91 | -21.9% |
| EPV | 45.33 - 68.58 | 56.96 | 14.4% |
| DDM - Stable | 24.14 - 62.75 | 43.45 | -12.8% |
| DDM - Multi | 33.58 - 72.60 | 46.44 | -6.7% |
| Market Cap (mil) | 668.32 |
| Beta | 0.71 |
| Outstanding shares (mil) | 13.42 |
| Enterprise Value (mil) | 583.96 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.00% |
| Cost of Debt | 4.25% |
| WACC | 6.71% |